Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

24.48 -0.48 (-1.94%)
Streaming Delayed Price Updated: 3:41 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics Plc ADR

< Previous 1 2 3 4 5 6 Next >
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Insights
Via Benzinga
Bicycle Therapeutics PLC (NASDAQ: BCYC) Making Surprising Moves in Friday Session
Via Investor Brand Network
14 Analysts Have This to Say About Bicycle Therapeutics
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
Via Benzinga
Analyst Ratings for Bicycle Therapeutics
Via Benzinga
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
Via Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
Via Benzinga
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
From Bicycle Therapeutics plc
Via Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
From Bayer
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Recap: Bicycle Therapeutics Q3 Earnings
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
From Bicycle Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.